Sign inJoin waitlistJoin the waitlist

Radhika Gogoi

Associate Professor · Wayne State University School of Medicine

Credentials: · · · · · ·

History

Wayne State University School of Medicine
Present

Gynecologic Oncology
Gynecologic Oncology Fellowship, New York University, New York, NY - 2005 -
2000–2003
Obstetrics and Gynecology
Obstetrics & Gynecology Residency, University of Rochester, Rochester, NY- 1996 -
1996–2000
University of Colorado Health Sciences Center, Denver, CO
HAHNEMANN UNIV SCH OF MED, PHILADELPHIA
1992–1996
Gannon University, Erie, PA
1988–1992

Research

Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells
Oncotarget · 2017 · Last of 6 authors · 93 citations
The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells
Breast Cancer Research · 2005 · First of 4 authors · Corresponding · 57 citations
Randomized Trial of Exercise on Quality of Life in Women With Ovarian Cancer: Women's Activity and Lifestyle Study in Connecticut (WALC)
Journal of the National Cancer Institute · 2017 · 56 citations

Robert Morris
7 papers · 1 as a fellow
Jennifer Ligibel
6 papers
PS
Peter Schwartz
6 papers
Thomas Rutherford
6 papers
VD
Venkata Dasari
6 papers
Matthew Anderson
5 papers
Rouba Ali-Fehmi
5 papers
Deepti Jain
4 papers · 4 as a resident
John Wallbillich
4 papers
TW
Terrence Wong
4 papers · 4 as a fellow
Thomas Herzog
4 papers
Adnan Munkarah
3 papers

Clinical trials

Relational Agents in Cervical Cancer Education (RACE)
Principal investigator · Completed
Radhika Gogoi
2020–2023
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2028
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Site PI · Unknown · Phase 3
Gynecologic Oncology Group
2012
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
Sub-investigator · Recruiting · Phase 2
Ira Winer
2020–2027